Diabetes, Advancing Chronic Kidney Disease Management Panel
- $512.20
- $392.95
- Save: 23.28%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Diabetes, Advancing Chronic Kidney Disease Management Panel #91713
13 Biomarkers
Also known as: Diabetes Advancing Chronic Kidney Disease Management Panel
Biomarkers
13
Calcium
Carbon Dioxide
Chloride
Creatinine
Creatinine, Random Urine
Hemoglobin
Microalbumin
Microalbumin/Creatinine
PARATHYROID HORMONE,
Phosphate (As Phosphorus)
Potassium
Sodium
Vitamin D, 25-Oh, Total
*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through a national lab. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.
The Diabetes, Advancing Chronic Kidney Disease Management Panel test contains 1 test with 13 biomarkers .
This panel is designed for individuals diagnosed as having diabetes mellitus whose kidney disease has advanced to Stage 3/4 impairment. The panel affords the opportunity to assess electrolytes, phosphorus, serum creatinine/eGFR, hemoglobin, microalbumin, parathyroid hormone, calcium, and vitamin D. The grouping of these tests, readily identifiable as elements that adhere to guideline recommendations, is intended to facilitate the ready adherence to professional society clinical practice guidelines. Components of the testing related to the Management of CKD in diabetes, as outlined in the Standards of Medical Care in Diabetes 2013. These recommendations are in broad agreement with those published by the National Kidney Foundation and the American Association of Clinical Endocrinologists.